Pharmacology · Antiviral Pharmacology

Opportunistic Viral Infections in Immunocompromised Hosts

Pathogens, antiviral availability, management principles, and diagnostic pitfalls

CMV colitis presents a critical diagnostic pitfall: blood CMV PCR is frequently undetectable or very low in isolated colitis because viral replication is confined to the colonic mucosa without producing systemic viremia — a negative blood PCR cannot rule out CMV colitis, and diagnosis requires colonoscopy with biopsy showing cytopathic effect on immunohistochemistry.
PTLD and EBV-associated disease after transplantation are driven by latently infected B cells, not by lytic viral replication — this is why acyclovir and ganciclovir, which require active viral DNA replication to be incorporated, have no meaningful clinical benefit in PTLD; the correct management is anti-CD20 immunotherapy with rituximab plus immunosuppression reduction, which depletes the EBV-infected B-cell reservoir.
No antiviral has demonstrated proven benefit in JC virus PML — the only intervention consistently associated with improved outcomes in HIV-associated PML is ART that restores CD4 counts above 200 cells/mm³, which reconstitutes JCPyV-specific T-cell immune surveillance; in natalizumab-associated PML, stopping the drug and performing plasma exchange to accelerate drug clearance restores lymphocyte CNS trafficking.
Chromosomally integrated HHV-6 (ciHHV-6) occurs in approximately 1% of the population and produces a stable, very high HHV-6 DNA signal in all nucleated cells — because this represents integrated germline DNA rather than active viral replication, antiviral therapy cannot suppress it and is not indicated; the clinical danger is treating ciHHV-6 as active infection, exposing patients to foscarnet or ganciclovir toxicity without benefit.
BKPyV nephropathy after kidney transplantation has no proven antiviral therapy — cidofovir, leflunomide, and IVIG have been used without robust evidence; the primary intervention is reduction of calcineurin inhibitor immunosuppression when plasma viral load exceeds 10,000 copies/mL, with the critical caveat that BKPyV nephropathy and rejection must be distinguished by allograft biopsy because their treatments are diametrically opposed.

Abbreviations: HSCT = hematopoietic stem cell transplant · SOT = solid organ transplant · PTLD = post-transplant lymphoproliferative disorder · PML = progressive multifocal leukoencephalopathy · BKPyV = BK polyomavirus · ciHHV-6 = chromosomally integrated HHV-6 · IRIS = immune reconstitution inflammatory syndrome · PLEX = plasma exchange · ATG = anti-thymocyte globulin · BAL = bronchoalveolar lavage

Antiviral Availability by Pathogen

Licensed Antivirals Available

Pathogens with Treatment Options

CMVGanciclovir, valganciclovir, foscarnet, cidofovir, letermovir, maribavir — most complete antiviral armamentarium
AdenovirusCidofovir off-label (with mandatory probenecid protocol); brincidofovir emerging in HSCT
HHV-6Foscarnet preferred; ganciclovir alternative — clinical trial data limited; active replication must be distinguished from ciHHV-6

No Effective Antiviral

Immune Reconstitution Only

EBV/PTLDNo antiviral benefit — PTLD driven by latent EBV in B cells, not lytic replication; acyclovir and ganciclovir are ineffective; manage with rituximab + reduced immunosuppression
JC Virus/PMLNo proven antiviral — cidofovir and cytarabine showed no benefit in controlled studies; restore immune surveillance via ART (HIV) or natalizumab withdrawal + PLEX (MS)

Immunosuppression Reduction

BKPyV Nephropathy

No proven antiviral therapy — cidofovir, leflunomide, and IVIG used without robust evidence
Screen: plasma BKPyV PCR monthly for first 12 months post-kidney transplant
Primary intervention: reduce calcineurin inhibitor dose when plasma viral load >10,000 copies/mL
Critical: biopsy distinguishes BKPyV nephropathy from rejection — treatments are diametrically opposed

CMV End-Organ Disease — Diagnostic and Management Points

Diagnostic Pitfall

CMV Colitis

Blood CMV PCR is frequently undetectable or very low in isolated CMV colitis — virus replicates locally in colonic mucosa without producing systemic viremia
Do NOT use a negative blood CMV PCR to rule out CMV colitis in symptomatic immunocompromised patients
Diagnosis requires colonoscopy with biopsy — CMV cytopathic effect on immunohistochemistry is the gold standard
Treatment: IV ganciclovir induction for 3–6 weeks, then oral valganciclovir consolidation; monitor clinically and endoscopically — not by blood PCR

Highest Mortality Syndrome

CMV Pneumonitis

HSCT recipients: mortality 30–50% despite antiviral therapy — most lethal CMV manifestation
Treatment: IV ganciclovir + IVIG (combination superior to ganciclovir alone in retrospective data)
Intervene early: treat CMV detected in BAL before symptoms of pneumonitis fully develop — pre-emptive treatment improves outcomes
CMV CNS DiseaseCombination ganciclovir + foscarnet for maximum antiviral potency; diagnose by CSF PCR (sensitivity >80%)

EBV/PTLD and JC Virus/PML — No Effective Antivirals

B-Cell Lymphoproliferative Disease

EBV/PTLD — Rituximab, Not Antivirals

Acyclovir and ganciclovir do not treat PTLD — PTLD is driven by latent EBV in B cells, not by active lytic replication that antivirals target
Monitor EBV viral load by PCR in high-risk HSCT recipients (T-cell-depleted grafts, ATG conditioning)
Rising EBV viral load → pre-emptive rituximab (anti-CD20 mAb) depletes EBV-infected B cells
Reduce immunosuppression when clinically feasible
Established PTLD unresponsive to rituximab: CHOP chemotherapy

CNS Demyelinating Disease

JC Virus/PML — Immune Reconstitution Only

No antiviral has proven clinical benefit in controlled studies — cidofovir and cytarabine both failed
HIV-associated PML: initiate or optimize ART to restore CD4 >200 cells/mm³ — only consistently effective intervention
PML-IRIS occurs in 10–30% of HIV patients starting ART with active PML — manage with corticosteroids
Natalizumab-associated PML: stop natalizumab immediately; plasma exchange (PLEX) accelerates drug clearance and restores lymphocyte CNS trafficking
Pembrolizumab (checkpoint inhibitor): signals of benefit in small case series — enhances JCPyV-specific T cells

HHV-6 — The ciHHV-6 Diagnostic Trap

ciHHV-6 — Chromosomally Integrated HHV-6 — Do Not Treat

Approximately 1% of the population carries HHV-6 integrated into the germline (ciHHV-6), producing stable, persistently very high HHV-6 DNA concentrations exceeding 5.5 log10 copies/mL in all nucleated cells. This represents integrated germline DNA — not active viral replication. Antivirals cannot suppress integrated DNA and are not indicated.

Treat only true HHV-6 reactivation: confirmed by fluctuating viral load, positive IgM anti-HHV-6, or compatible clinical syndrome. HHV-6B encephalitis (bilateral hippocampal T2 signal on MRI + positive CSF PCR): treat with foscarnet as preferred agent for 3–6 weeks. The clinical danger of ciHHV-6 is treating a normal variant as active infection, exposing patients to foscarnet nephrotoxicity and electrolyte disturbances without benefit.

BKPyV Nephropathy — Immunosuppression Reduction Is the Intervention

Screen kidney transplant recipients with plasma BKPyV PCR monthly for the first 12 months. Plasma viral load above 10,000 copies/mL triggers reduction of calcineurin inhibitor dose. No antiviral has robust evidence — cidofovir, leflunomide, and IVIG have all been used empirically. The central tension is balancing sufficient immunosuppression reduction to control BKPyV replication against the risk of precipitating acute rejection.

Allograft biopsy is essential when viral load is rising or renal function is declining — it is the only reliable way to distinguish BKPyV nephropathy from rejection. These two diagnoses require opposite management: rejection requires increased immunosuppression, BKPyV nephropathy requires reduced immunosuppression. Making this distinction incorrectly can be fatal to the allograft.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 49: Antiviral Agents	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 56: Antiviral Agents (Non-Retroviral)	McGraw-Hill; 2023
Ljungman P et al.	Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials	Clin Infect Dis. 2017
Boeckh M, Ljungman P	How we treat cytomegalovirus in hematopoietic cell transplant recipients	Blood. 2009
Styczynski J et al.	Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation	Haematologica. 2016
Trappe RU et al.	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder	Lancet Oncol. 2012
Ljungman P et al.	Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the infectious diseases working party of the European Group for Blood and Marrow Transplantation	Bone Marrow Transplant. 2003
Hirsch HH et al.	Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients	N Engl J Med. 2002
Berger JR, Aksamit AJ, Clifford DB et al.	PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section	Neurology. 2013
Tan CS, Koralnik IJ	Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis	Lancet Neurol. 2010
Lund TC et al.	HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: rare or underdiagnosed? Bone Marrow Transplant	2006
Zerr DM et al.	A population-based study of primary human herpesvirus 6 infection	N Engl J Med. 2005
Huang ML et al.	Chromosomally integrated human herpesvirus 6 in transplant recipients	Clin Infect Dis. 2014